An overview of micafungin as a treatment option for invasive candidiasis in pediatric patients younger than 4 months old.

, more frequently resistant to polyenes than to echinocandins and showing high rates of resistance to azoles, could render micafungin even more crucial for guaranteeing an efficacious antifungal treatment for invasive candidiasis in pediatric patients younger than 4 months old.